In China’s largest pivotal trial ever -- 21, 000 people -- Qiagen’s TB test showed the incidence of latent TB infection in China’s population is 18.8%. That was far lower than the 28.8% indicated by the century-old TB skin test, which registered many false positives. The QuantiFERON-TB Gold (QFT®) test, an interferon-gamma release assay, was approved for use in China in 2013. By lowering the estimate of China’s at-risk population, the test renders a TB preventative program more feasible. Qiagen is headquartered in the Netherlands.
Help employers find you! Check out all the jobs and post your resume.
